Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.

Expert opinion on drug metabolism & toxicology - 1 Apr 2023

Hong Eunjin, Shi Alan, Beringer Paul

Abstract excerpt

INTRODUCTION: Cystic fibrosis (CF) is characterized by mucus accumulation impairing the lungs, gastrointestinal tract, and other organs. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators (ivacaftor, tezacaftor, elexacaftor, and lumacaftor) significantly improve lung function and nutritional status; however, they are substrates, inhibitors, and/or inducers of certain CYP enzymes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Chloride Channel Agonists
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Combinations

Share to Drug Interactions

Share to Mutation

Source

Identifiers

PMID: 37259485
DOI: 10.1080/17425255.2023.2220960

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.PMID 37259485Read ↗

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®.Semantic proximity Read ↗

A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

Tezacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in FranceSemantic proximity Read ↗

Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.Semantic proximity Read ↗

Use of CFTR modulators in special populations, part 3: Solid organ transplant.Semantic proximity Read ↗

Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.Semantic proximity Read ↗

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Semantic proximity Read ↗

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.Semantic proximity Read ↗

A safety evaluation of ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.